<DOC>
	<DOC>NCT02107404</DOC>
	<brief_summary>The purpose of this study is to determine whether DCVAC/PCa added after radical primary prostatectomy can improve PSA doubling times for patients with localized Prostate Cancer.</brief_summary>
	<brief_title>Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 years and older Histologically confirmed pT2 prostate cancer Post radical prostatectomy PSA values measured after the value greater than 0.020 ng/mL resulted in PSA doubling time (PSADT) equal or less than 12 months Salvage radiotherapy na√Øve with PSA increase within 2 years or after salvage radiotherapy with PSA not higher than 1 ng/ml Eastern Cooperative Oncology Group (ECOG) 02 Confirmed brain and/or leptomeningeal metastases Prior androgen deprivation therapy or orchiectomy for prostate cancer Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater Other uncontrolled intercurrent illness Treatment with immunotherapy against prostate cancer Clinically significant cardiovascular disease Active autoimmune disease requiring treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>